Stock MRK MERCK & CO., INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News Merck & Co., Inc. Euronext Paris

Equities

MRK

US58933Y1055

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Global markets live: Shell, UBS, Boeing, Berkshire Hathaway, Exxon...
Our Logo
Merck: FDA approves Capvaxive pneumococcal vaccine
CF
Merck: new FDA approval for Keytruda
CF
Merck - U.S. FDA Approves CAPVAXIVE for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults
AQ
FDA Approves Merck s KEYTRUDA plus Carboplatin and Paclitaxel as Treatment for Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma
AQ
Big tech still runs the show
Our Logo
Sector Update: Health Care Stocks Flat to Lower Premarket Tuesday
MT
Wall Street set for flat open after soft retail sales data
RE
Merck Receives FDA Approval for Capvaxive, Triggers $2 Million Payment for Ligand Pharmaceuticals
MT
Merck Gets FDA Approval for Keytruda Plus Carboplatin and Paclitaxel for Endometrial Carcinoma Treatment
MT
Merck Get FDA Approval for Keytruda to Treat Endometerial Cancer
DJ
U.S. FDA Approves CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults
BU
US FDA approves Merck's pneumococcal vaccine for adults
RE
Merck Announces U.S. FDA Approves Capvaxive (Pneumococcal 21-Valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults
CI
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Carboplatin and Paclitaxel as Treatment for Adult Patients With Primary Advanced or Recurrent Endometrial Carcinoma
BU
Merck Announces FDA Approves Merck's Keytruda (Pembrolizumab) Plus Carboplatin and Paclitaxel as Treatment for Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma
CI
FDA Approves Merck's Vaccine For Adult Invasive Pneumococcal Disease
DJ
Ex-dividend day
FA
High-risk health workers can get routine Ebola vaccine, Gavi says
RE
AbbVie inks immune disorder drug licensing deal with China's FutureGen
RE
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MRK Stock
  4. MRK Stock
  5. News Merck & Co., Inc.